T. Rowe Price Group

Arbor Biotechnologies, Inc., founded in 2016 and headquartered in Cambridge, Massachusetts, operates as a bio-discovery company in the biotechnology sector. The company focuses on developing genomic tools that enhance human health and sustainability. Utilizing a combination of artificial intelligence, genome sequencing, gene synthesis, and high-throughput screening, Arbor's platform accelerates the discovery of proteins and facilitates human diagnostic development. The technology aggregates genomic sequence data through AI and machine learning, enabling drug developers to replace entire genes and precisely correct mutations. This approach aims to streamline the development of curative treatments for previously incurable genetic diseases, ultimately improving the lives of patients affected by such conditions.

KoBold Metals operates as an AI-powered mineral exploration company focused on discovering materials essential for the electric vehicle and renewable energy sectors. The company utilizes advanced software that aggregates and structures extensive scientific datasets, including geochemical, geophysical, and geological information. By applying various analytical techniques such as ensemble machine learning and computer vision, KoBold predicts subsurface compositions in a statistically valid manner. This innovative approach enhances the exploration efficiency for mineral resources, particularly cobalt, which is crucial for the electric vehicle industry. By merging ore-deposit science with big data and scientific computing, KoBold Metals aims to identify new sources of cobalt and support the sustainable supply chain for emerging technologies.

ArsenalBio is a programmable cell therapy company established in 2019, focused on developing effective and accessible immune cell therapies, primarily targeting cancer treatment. The company utilizes advanced technologies, including CRISPR-based genome engineering, synthetic biology, and machine learning, to create a new paradigm for discovering and developing immune cell therapies. ArsenalBio's innovative approach aims to enhance the efficacy and safety of T-cell therapies while reducing costs for providers and broadening patient access. By employing a full-stack research and development engine, ArsenalBio generates multifunctional T-cell medicines through the precise insertion of large synthetic DNA sequences, enabling clinicians to utilize next-generation autologous T-cell therapies to combat cancer more effectively.

MBX Biosciences, Inc. is a biotechnology company based in Carmel, Indiana, specializing in the development of therapeutics for rare endocrine disorders. Established in 2018, the company focuses on creating peptides aimed at treating genetic diseases that affect glandular hormones, which play a crucial role in the body’s chemical messaging system. By targeting conditions with inadequate treatment options, MBX Biosciences is dedicated to discovering, developing, and commercializing innovative endocrine therapeutics.

Waymo is a self-driving technology company focused on enhancing mobility by creating safe and efficient transportation solutions. Established from advancements in Google's research since 2009, Waymo aims to improve the movement of people and goods through its innovative software and sensor technology. In 2015, the company marked a significant milestone by conducting the world's first fully autonomous trip on public roads in a vehicle devoid of traditional driving controls. Waymo continually refines its technology through extensive simulation testing, accumulating over one billion miles of virtual testing annually, while its autonomous vehicles have logged more than two million miles on public roads in four U.S. cities. By employing integrated sensors and artificial intelligence, Waymo's technology is designed to detect various obstacles such as pedestrians, cyclists, and road conditions, ensuring a safe and convenient on-demand travel experience for users.

Bluejay Therapeutics is a biopharmaceutical company dedicated to developing cures for infectious diseases, with a primary focus on chronic Hepatitis B. This condition poses a significant global health challenge, and the company aims to address the urgent need for effective treatments. Bluejay is advancing two innovative therapeutic approaches: best-in-class fully human IgG1 anti-HBs monoclonal antibodies and first-in-class oral small molecule inhibitors targeting HBsAg. These strategies are designed to reduce hepatitis B surface antigen levels and restore adaptive immunity, potentially leading to a functional cure for patients. Additionally, the company’s research encompasses therapeutic options for chronic Hepatitis D, further solidifying its commitment to improving immunity and recovery for individuals affected by serious viral and liver diseases.

Endeavor BioMedicines is a clinical-stage company based in Solana Beach, California, that focuses on developing innovative treatments for pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF). Founded in 2018, the company is working on a small-molecule inhibitor designed to target the underlying causes of this progressive lung disease. The treatment aims to not only halt the progression of IPF but also has the potential to reverse its effects, offering healthcare professionals a new avenue for precision treatments in managing terminal conditions. Endeavor BioMedicines strives to improve patient outcomes and enhance quality of life for those affected by this challenging illness.

Obsidian Therapeutics develops innovative cell and gene therapies aimed at enhancing adoptive immunotherapy for cancer patients. Founded in 2015 and based in Cambridge, Massachusetts, the company focuses on creating next-generation therapies that utilize pharmacologic operating systems to provide precise control over protein activity within cells. This technology allows for the development of adoptive cell therapies with advanced functionalities that can be managed by physicians using simple, safe, and orally active medications. By offering improved control over treatment, Obsidian Therapeutics aims to provide better outcomes for patients compared to existing cell therapy options.

Sionna Therapeutics was formed in late 2019, leveraging 10 years of large pharma scientific investment and expertise. Our experienced scientific team has been on a mission to fully normalize CFTR function. In the three decades since the discovery of the genetic defects that cause cystic fibrosis (CF), researchers have made remarkable advances for patients. Yet the ultimate goal of CF drug development – to fully normalize the function of CFTR, the key protein leading to the pathology of CF – has remained out of reach.

Lambda is a technology company specializing in deep-learning infrastructure. It provides cloud computing services tailored for large-scale artificial intelligence training and inference. The company offers servers and workstations pre-configured with popular machine learning frameworks, allowing clients to simplify and accelerate the development of complex AI models for tasks such as natural language processing and drug discovery. Lambda's product range includes on-premises GPU hardware and cloud-hosted GPUs, empowering AI engineers to construct, test, and deploy AI products efficiently and securely at scale.

Lilac Solutions, Inc. is a mining technology company focused on lithium extraction, providing innovative technology and services to lithium producers. The company specializes in ion exchange beads and continuous brine processing systems, which enable the efficient production of high-purity lithium solutions from various brine resources. This technology, grounded in ion-exchange theory, allows lithium producers to enhance project development, improve lithium recovery rates, and optimize operational efficiency while also minimizing costs and environmental impact. Lilac Solutions serves industries such as electric vehicles and renewable energy storage. Incorporated in 2015, the company is headquartered in Oakland, California.

Odyssey Therapeutics is a biotechnology company focused on the development of next-generation immunomodulators and oncology medicines. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, unlocking high-potential targets while reducing the risk of attrition during the development process. Odyssey is committed to advancing precision medicine in the healthcare sector, with a product pipeline designed to facilitate a faster transition to clinical development, thereby improving treatment options for patients with various health conditions.

Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies through its unique platform. The company specializes in Generative Biology, a machine learning-driven approach that analyzes known proteins to understand the relationship between genetic sequences, protein structure, and function. This enables the creation of novel therapeutic proteins, including antibodies, enzymes, and receptors, which are designed to interact specifically and effectively with various therapeutic targets. Founded in 2018 and rebranded from Generate Biologics in 2020, Generate Biomedicines aims to streamline the drug discovery process by generating new biological molecules with significant therapeutic potential.

Sortera Alloys manufactures low-cost, high-quality metal alloys for domestic manufacturing using its artificial intelligence technology. Sortera Alloys is a company based in Fort Wayne, Indiana, and was established in 2020.

ADARx Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on the research and development of RNA editing therapeutics. Founded in 2019, the company specializes in the precise targeting and correction of single point mutations on mRNA transcripts using a proprietary platform that leverages endogenous enzymes known as adenosine deaminase acting on RNA (ADAR). This innovative approach aims to restore the production of functional proteins, addressing genetic mutations that lead to various diseases. ADARx Pharmaceuticals is developing a diverse pipeline of ribonucleic acid targeting therapeutics aimed at treating conditions across multiple therapeutic areas, including genetic disorders, cardiometabolic diseases, complement-mediated diseases, and central nervous system disorders.

Ring Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing gene therapies through its innovative Anellovector platform. This platform leverages the biology of the human commensal virome to create redosable and targetable DNA therapies that address several limitations of existing gene therapies, such as restricted access to various tissues, risks associated with genomic integration, and issues with tolerability. Founded in 2017, the company aims to expand the applications of gene therapy beyond traditional gene replacement, targeting a wide range of conditions including genetic disorders, ophthalmology, oncology, and metabolic diseases. By doing so, Ring Therapeutics seeks to provide healthcare solutions that allow for a broader array of therapeutic modalities and improved patient outcomes.

Cleerly is a healthcare company focused on improving the prevention of heart attacks through innovative digital care pathways. It aims to establish a new standard for coronary artery disease by combining advanced clinical science with cutting-edge artificial intelligence. Cleerly's platform offers a non-invasive approach that quantifies and characterizes plaque buildup in coronary arteries, enhancing the understanding of cardiovascular health. By providing actionable clinical insights, the company enables healthcare providers to better identify at-risk patients and implement early treatment strategies. Ultimately, Cleerly's data-driven solutions aspire to deliver significant value to the healthcare system while improving heart health outcomes for individuals susceptible to heart attacks.

YuLife is a London-based insurance company founded in 2016 that focuses on promoting well-being through its innovative insurance platform. By integrating gamification and behavioral science, YuLife offers life and medical insurance plans that incentivize healthy living. Users are encouraged to engage in activities such as walking and meditation, earning rewards like air miles, vouchers, and gift cards as they pursue a healthier lifestyle. This approach not only supports individual wellness but also helps businesses ensure their employees are insured while fostering a culture of health and motivation. YuLife aims to transform financial products into a force for good, making everyday wellness accessible to all.

Tessera Therapeutics is an early-stage life sciences company focused on pioneering Gene Writing technology, which allows for the permanent modification of the human genome. This innovative approach enables scientists and clinicians to introduce therapeutic messages into the genome, offering a potential cure for diseases at their source. By building on recent advancements in gene therapy and gene editing, Tessera Therapeutics aims to address significant limitations in these areas, enhancing their applicability and effectiveness. Founded by Flagship Pioneering, the company is positioned to transform genetic medicine and improve patient care through its groundbreaking technology.

Epirus, Inc. is a technology company based in Hawthorne, California, specializing in the design and development of advanced defense systems that utilize artificial intelligence and directed energy. Founded in 2018, the company focuses on creating solid-state, software-defined high-power microwave solutions aimed at countering unmanned aircraft systems and other asymmetric threats. Its flagship product, ELECTROMAGNETIC PULSE, serves as a counter-infrastructure solution that can simultaneously target multiple threats, effectively neutralizing drones and swarms. By integrating AI and machine learning with advanced electronics, Epirus enhances the detection and tracking of objects of interest, offering innovative capabilities in electronic warfare and power management for both defense and commercial sectors.

DNA Script SAS, established in 2014 and headquartered in Paris, France, specializes in synthetic biology tools. The company's core product, SYNTAX, is a revolutionary benchtop DNA printer that uses enzymatic technology to rapidly produce synthetic oligonucleotides, genes, pathways, and genomes. This innovative approach empowers life science researchers and labs to print their own synthetic DNA, enhancing workflow control and accelerating access to results, thereby advancing breakthroughs in life science and human health.

Redwood Materials, Inc. is a Nevada-based company focused on advancing sustainable battery recycling technologies to create a circular supply chain for lithium-ion batteries. Founded by JB Straubel in 2017, Redwood specializes in the recycling and processing of end-of-life batteries and electronics to recover critical materials such as lithium, nickel, cobalt, copper, and various metals. The company currently receives approximately 10 GWh of used batteries annually and aims to scale its production of anode and cathode materials to 100 GWh by 2025, sufficient for manufacturing over one million electric vehicles each year. By providing environmentally sound solutions for recycling and refining, Redwood supports industries including electric vehicles, renewable energy storage, and consumer electronics, thereby contributing to a reduction in the environmental impact of battery production and usage.

Element Biosciences, Inc., established in 2017 and headquartered in San Diego, California, specializes in developing innovative genetic analysis tools for research and diagnostic markets. The company's core business revolves around its disruptive DNA sequencing technology, which encompasses surface chemistry, sequencing chemistry, detection methods, and data analysis. Element Biosciences aims to enhance accessibility to next-generation sequencing by offering a modular, high-performing platform that delivers high-quality data and workflow flexibility, thereby reducing run and capital costs.

Jetti Resources is a company based in Vancouver, Canada, that specializes in developing hydrometallurgical technology for the extraction of metals from mineral ores. Founded in 2014, Jetti focuses primarily on extracting copper from low-grade primary sulfides, including chalcopyrite, which is the most abundant copper mineral ore. The company has developed a proprietary catalytic technology that enhances copper recovery from vast quantities of ore, addressing significant challenges in mineral processing. This technology integrates with existing heap leaching methods and downstream operations, allowing industrial clients to improve copper yields in a cost-effective and environmentally sustainable manner. Additionally, Jetti's technology is applicable for the extraction of zinc and nickel from sulfide ores, further diversifying its capabilities in mineral processing.

Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company specializes in providing a comprehensive analytics platform that analyzes the molecular contents of food and ingredients. Its offerings include Clear Dx™ and Clear Safety™, which utilize next-generation sequencing and data analytics for food safety testing and infectious disease surveillance. Clear Labs serves food manufacturers, suppliers, and retailers by ensuring transparency throughout the supply chain and testing products for various factors such as authenticity, contamination, allergens, and nutritional content. The platform delivers actionable insights that enhance safety and operational efficiency while supporting public health initiatives. Through its integrated genomics system, Clear Labs aims to simplify complex diagnostics across clinical and applied markets, making genomic insights accessible to labs, hospitals, and businesses.

Gyroscope is a clinical-stage gene therapy company that specializes in developing treatments for retinal diseases, particularly focusing on Age-related Macular Degeneration (AMD), a major cause of blindness. The company leverages advancements in understanding the complement system's role in eye diseases and uses gene therapy as a therapeutic approach. Gyroscope's lead investigational therapy, GT005, is designed to be administered as a one-time treatment under the retina, aiming to restore balance to an overactive complement system by enhancing the production of the Complement Factor I protein. Currently, GT005 is undergoing evaluation in multiple clinical trials, including a Phase I/II trial named FOCUS and two Phase II trials called EXPLORE and HORIZON. Founded in 2016 in Stevenage, Herefordshire, by Andrew Lotery, David Kavanagh, and Peter Lachmann, Gyroscope seeks to provide innovative solutions for patients suffering from retinal diseases.

Insitro, Inc. is a data-driven company focused on drug discovery and development, particularly targeting nonalcoholic steatohepatitis (NASH). Founded in 2018 by Daphne Koller and based in South San Francisco, California, Insitro harnesses machine learning and high-throughput biology to revolutionize the process of drug discovery. The company creates extensive functional genomic data sets and integrates them with patient data through innovative machine learning techniques. This approach allows Insitro to build predictive models that enhance target selection, streamline the design of therapeutics, and optimize drug development strategies. By addressing critical challenges in pharmaceutical research and development, Insitro aims to accelerate the delivery of new and effective treatments to patients.

Tenaya Therapeutics is a biotechnology company based in South San Francisco, California, focused on developing innovative therapies for heart disease, particularly heart failure. Established in 2016, the company employs three main platforms to address the underlying causes of heart disease: a cellular regeneration platform that reprograms cardiac fibroblasts into cardiomyocytes using proprietary transcription factors, a gene therapy platform for targeted delivery of therapeutic payloads, and a precision medicine approach tailored to individual patients. Through these platforms, Tenaya Therapeutics aims to enable the regeneration of heart tissue and tackle various forms of cardiomyopathies, leveraging advanced research in cardiac development and regeneration.

Vividion Therapeutics, Inc. is a biotechnology company based in San Diego, California, that focuses on developing innovative therapeutics to address significant unmet medical needs. Established in 2013, Vividion utilizes a pioneering platform for proteome-wide small molecule drug discovery, which combines advanced synthetic chemistry techniques with chemical proteomics. This approach allows the company to expand the druggable proteome and target challenging proteins, ultimately enabling the discovery of transformative treatments for serious illnesses. Vividion's scientific foundation stems from experts in chemical biology and synthetic chemistry at The Scripps Research Institute, reflecting its commitment to advancing therapeutics that can significantly improve patient outcomes.

Rad Power Bikes LLC, based in Seattle, Washington, is a leading manufacturer and retailer of electric bicycles in North America. Founded in 2015, the company specializes in designing feature-rich e-bikes suitable for both on and off-road use, catering to a diverse range of consumer needs. In addition to its electric bikes, Rad Power Bikes offers a variety of accessories such as bags, fenders, racks, and safety products, as well as replacement parts like batteries and tires. The company operates on a direct-to-consumer model, selling its products primarily through online platforms, which allows it to provide affordable and accessible transportation solutions. With a rapidly expanding workforce exceeding 700 employees, Rad Power Bikes is committed to revolutionizing electric mobility and promoting energy-efficient transportation options.

Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, focused on developing innovative vaccines using its proprietary Multiple Antigen Presenting System (MAPS) technology. This approach allows for the combination of protective polysaccharides and proteins into a single vaccine, thereby enhancing immune responses against a variety of infectious diseases affecting both children and adults. Affinivax targets several significant pathogens, including Streptococcus pneumoniae, bacterial nosocomial infections, Salmonella typhi, and Staphylococcus aureus. The company aims to create vaccines that not only provide broader disease coverage compared to existing options but also address infectious diseases lacking effective immunization strategies. Founded in 2014, Affinivax benefits from the expertise of leading professionals in infectious diseases and vaccines, and it has received backing from the Bill & Melinda Gates Foundation, along with an exclusive license from Boston Children’s Hospital for its MAPS technology.

FogPharma is a biotechnology company focused on developing innovative cancer therapies through its unique cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, the company aims to address cancer-causing proteins that are typically inaccessible to traditional treatments. By collaborating with leading experts in cancer biology and therapy, FogPharma is creating a new class of medicines designed to neutralize these challenging targets. The company is supported by a diverse group of private and institutional investors, which enables it to pursue its mission of delivering transformative cancer treatments. FogPharma is dedicated to improving the lives of patients and their families, striving to extend both life expectancy and quality of life.

Flexe, Inc. operates a cloud-based marketplace that connects organizations seeking additional warehousing and fulfillment services with those that have surplus capacity. Founded in 2013 and headquartered in Seattle, the company specializes in omnichannel logistics solutions, including eCommerce fulfillment, retail distribution, and same-day delivery. Flexe's platform addresses the challenges of inventory overflow and fulfillment needs by creating an open logistics network, allowing clients such as retailers, wholesalers, manufacturers, and logistics companies to optimize their distribution capabilities. By integrating technology and flexible economic models, Flexe enables its customers to enhance their operational efficiency and respond swiftly to market demands.

Imago BioSciences is a clinical-stage biotechnology company based in Redwood City, California, that specializes in developing innovative medicines for hematologic diseases. Founded in 2012, the company focuses on therapeutics that target genetic and epigenetic factors, specifically through the inhibition of lysine-specific demethylase 1 (LSD1), an enzyme crucial in blood cell production. Imago BioSciences aims to address significant medical challenges associated with conditions such as leukemia, myelodysplastic syndrome, and other bone marrow disorders. Its lead product candidate, Bomedemstat, is an orally available small molecule designed to treat certain myeloproliferative neoplasms, with the goal of altering disease progression and improving the quality and longevity of patients' lives.

Nuro, Inc. is a technology company based in Mountain View, California, that specializes in the development of self-driving vehicles specifically designed for local goods transportation. Incorporated in 2016, Nuro aims to transform local commerce through its fleet of fully autonomous, electric vehicles that facilitate the delivery of a wide range of products, including food and pharmaceuticals. By enabling retailers to efficiently and safely deliver goods to customers, Nuro enhances the convenience of local commerce and meets the growing demand for autonomous delivery solutions.

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

Alignment Health is a healthcare organization focused on providing tailored care solutions for seniors, primarily through Medicare Advantage plans. By offering a consumer-centric platform, it allows seniors to choose their healthcare coverage and services annually. The company emphasizes a combination of technology and clinical coordination to enhance health outcomes, facilitating care through various channels, including phone, online, and in-person settings. Additionally, Alignment Health supports its partners and patients with risk management and customized services, ensuring a comprehensive approach to healthcare delivery.

Generation Bio is a genetic medicines company based in Cambridge, Massachusetts, that specializes in developing innovative gene therapies for both rare and prevalent diseases. Founded in 2016 and originally named Torus Therapeutics, the company focuses on treating conditions primarily affecting the liver and retina, as well as diseases of skeletal muscle, the central nervous system, and oncology. Generation Bio employs a proprietary non-viral platform that includes a high-capacity DNA construct known as closed-ended DNA (ceDNA) and a cell-targeted lipid nanoparticle delivery system (ctLNP). This platform aims to deliver genetic payloads effectively across various tissues and allows for redosable treatments tailored to individual patient needs. Through its advanced manufacturing processes, Generation Bio seeks to expand access to gene therapies and provide durable solutions for patients with both rare and common diseases.

Allbirds, founded in 2015 and based in San Francisco, is an apparel and fashion company specializing in eco-friendly footwear. It manufactures and sells a variety of shoe styles for men, women, and children, including wool runners, tree runners, and loungers, using premium natural materials. The company's mission is to create sustainable footwear that combines comfort, good design, and environmental responsibility. Allbirds operates through its own stores, retail partners, and an online platform, with a significant portion of its revenue coming from the United States market.

Convoy, Inc. operates an online marketplace that provides digital freight network services, enabling users to book local and regional trucks on demand for transporting goods, ranging from single pallets to full truckloads. The company offers a mobile application that features real-time shipment tracking, status updates, and ensures on-time deliveries. Founded in 2015 and based in Seattle, Washington, Convoy aims to enhance efficiency in the trucking industry, which is valued at $800 billion and is responsible for significant carbon emissions from empty trucks. By utilizing technology and data, Convoy addresses issues of waste and inefficiency, ultimately saving money for shippers, increasing earnings for drivers, and reducing carbon waste. The platform facilitates instant quotations, online bookings, automated loading suggestions, and online payments, all of which contribute to improved operational efficiency and cost reduction for clients.

Gusto is a software-as-a-service company specializing in Human Capital Management (HCM). It offers a comprehensive platform that simplifies payroll processing, benefits administration, and employee management for small businesses. Gusto’s services include payroll management, time and attendance tracking, and employee onboarding, all designed to meet the various HR needs of its clients. By providing an integrated system for managing employee benefits, including health, dental, and vision insurance, Gusto enables businesses to effectively support their workforce. This platform is aimed at streamlining administrative tasks, allowing small business owners to focus on their core operations while ensuring compliance with employment regulations.

Framebridge, Inc. specializes in custom framing solutions for art and photographs, offering a streamlined online service that prioritizes customer experience. Founded in 2014 and based in Washington, D.C., the company allows users to select from a curated range of contemporary frame styles, upload images, or send physical items for personalized framing. The expert team at Framebridge handcrafts frames to meet each customer's specifications, ensuring high-quality results. Finished products are shipped directly to consumers, typically arriving within days and ready to hang. Pricing is transparent and based on the size of the framed item, starting at $39 and including free shipping. Framebridge operates manufacturing facilities in Richmond, Kentucky, and Lanham, Maryland, and has attracted investments from notable firms and individuals in the retail and technology sectors.

Checkr, Inc. is a technology-driven company focused on the background check industry, offering a comprehensive range of screening services, including criminal record checks, driving checks, and identity verification. Founded in 2014 and headquartered in San Francisco, California, Checkr utilizes advanced technology and data sources to deliver faster and more efficient background checks compared to traditional providers. The company emphasizes fairness and transparency in hiring, enabling businesses across various sectors, including financial services, healthcare, and staffing, to enhance their hiring processes. Checkr also provides compliance services and security solutions, ensuring a secure and streamlined experience for both employers and candidates. With its innovative platform, Checkr aims to improve the overall applicant experience while supporting companies in navigating the complexities of today's workforce dynamics.

RefleXion Medical Inc. is a medical equipment company specializing in the development of biologically-guided radiotherapy systems for cancer treatment. Its flagship innovation, the RefleXion X1 machine, is designed to deliver advanced radiation therapies such as stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS). The company's biologically-guided radiotherapy (BgRT) technology utilizes positron-emission tomography (PET) imaging data to allow tumors to continuously signal their location during treatment, enabling the possibility of treating multiple tumors in a single session, especially in cases of metastasized cancers. This real-time adaptation to the biological characteristics of tumors represents a significant advancement in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic partnerships with Telix Pharmaceuticals Limited and HealthMyne Inc. to further its mission in cancer treatment innovation.

ShockWave Medical, Inc. is a medical device company based in Santa Clara, California, focused on developing and commercializing intravascular lithotripsy technology to treat calcified plaque associated with peripheral vascular, coronary vascular, and heart valve diseases. The company offers a range of catheters, including M5 for above-the-knee peripheral artery disease, C2 for coronary artery disease, and S4 for below-the-knee peripheral artery disease. Its Lithoplasty™ technology utilizes sonic pressure waves to facilitate the treatment of rigid vascular and valvular lesions, allowing for improved angioplasty outcomes and reduced reliance on stents. This innovative approach enhances vessel preparation before procedures such as drug eluting balloon placement and trans-catheter aortic valve replacement. ShockWave Medical serves a diverse clientele, including interventional cardiologists, vascular surgeons, and interventional radiologists, through a network of sales representatives, managers, and distributors across the United States and Europe. Incorporated in 2009, the company is committed to transforming cardiovascular care and improving patient outcomes.

Wheels Up is a membership-based private aviation company that specializes in on-demand flight services in the United States. By leveraging data and technology, it connects consumers with safety-vetted private aircraft, offering both programmatic and charter options. The company aims to reduce the upfront costs associated with private flying while providing flexibility, service, and safety to its members. Through its mobile app, users can easily book flights, manage accounts, and access ride-share opportunities. Additionally, members participate in the Wheels Down program, which enhances their travel experiences. Wheels Up operates a diverse fleet, utilizing owned, leased, and chartered aircraft to provide a wide range of global travel alternatives.

Evolve is a hospitality company with a mission to make renting a vacation home easy for both guests and homeowners. They help guests rest easy knowing our homes are verified, our support is 24/7, and if their stay doesn’t meet our standards, we’ll make it right. We also make vacation rental stress-free for homeowners, partnering with them to book more and keep more of what they earn thanks to our industry-low 10% management fee.

Outset Medical, Inc. is a medical technology company based in San Jose, California, focused on innovating hemodialysis systems. The company has developed Tablo, a compact dialysis machine designed for use in both acute and chronic care settings. This system integrates essential features such as water purification, on-demand dialysate production, and advanced software capabilities, including wireless data connectivity and sensor-based automation. By simplifying the dialysis process, Tablo aims to reduce costs and enhance the experience for both patients and healthcare providers. Founded in 2003 and originally named Home Dialysis Plus, Ltd., Outset Medical rebranded in 2015 to reflect its commitment to transforming dialysis care.

ShockWave Medical, Inc. is a medical device company based in Santa Clara, California, focused on developing and commercializing intravascular lithotripsy technology to treat calcified plaque associated with peripheral vascular, coronary vascular, and heart valve diseases. The company offers a range of catheters, including M5 for above-the-knee peripheral artery disease, C2 for coronary artery disease, and S4 for below-the-knee peripheral artery disease. Its Lithoplasty™ technology utilizes sonic pressure waves to facilitate the treatment of rigid vascular and valvular lesions, allowing for improved angioplasty outcomes and reduced reliance on stents. This innovative approach enhances vessel preparation before procedures such as drug eluting balloon placement and trans-catheter aortic valve replacement. ShockWave Medical serves a diverse clientele, including interventional cardiologists, vascular surgeons, and interventional radiologists, through a network of sales representatives, managers, and distributors across the United States and Europe. Incorporated in 2009, the company is committed to transforming cardiovascular care and improving patient outcomes.

OfferUp, Inc. is an online platform based in Bellevue, Washington, that facilitates local buying and selling of a wide range of items. Founded in 2011 by Arean Van Veelen and Nick Huzar, the platform allows users to post items for sale and connect with potential buyers in their vicinity, including friends and community groups. Users can browse a diverse array of categories such as electronics, furniture, vehicles, and collectibles, with new postings available daily. The platform emphasizes ease of communication, enabling users to message each other directly to negotiate prices and arrange meetings. OfferUp aims to create a convenient marketplace for individuals looking to trade goods locally.

Magic Leap is an American startup specializing in Augmented Reality (AR) technology. The company develops proprietary wearable hardware that merges digital imagery with the real world, creating immersive AR experiences indistinguishable from reality. Their innovative Dynamic Digitized Lightfield Signal generates computer-generated 3D images that harmonize with human senses, enabling users to interact with digital devices in a visually cinematic manner. Magic Leap aims to redefine how users access screens and visualize data by combining inherent visual ability with mobile computing technology.

Audentes Therapeutics, a clinical stage biotechnology company based in San Francisco, specializes in developing gene therapy products aimed at treating serious, life-threatening rare diseases resulting from single gene defects. The company is advancing several therapeutic candidates, including AT132 for X-linked myotubular myopathy, AT342 for Crigler-Najjar syndrome, and AT845, which is in preclinical studies for Pompe disease. Additionally, Audentes is developing vectorized antisense treatments for Duchenne muscular dystrophy and myotonic dystrophy type 1. It has established collaborative agreements with Genethon and the University of Pennsylvania to further research and commercialization efforts for these therapies. Founded in 2012, Audentes Therapeutics was acquired by Astellas Pharma in January 2020 and operates under the name Astellas Gene Therapies, focusing on gene therapy research, development, and future commercialization.

OfferUp, Inc. is an online platform based in Bellevue, Washington, that facilitates local buying and selling of a wide range of items. Founded in 2011 by Arean Van Veelen and Nick Huzar, the platform allows users to post items for sale and connect with potential buyers in their vicinity, including friends and community groups. Users can browse a diverse array of categories such as electronics, furniture, vehicles, and collectibles, with new postings available daily. The platform emphasizes ease of communication, enabling users to message each other directly to negotiate prices and arrange meetings. OfferUp aims to create a convenient marketplace for individuals looking to trade goods locally.

Doximity is a digital platform designed exclusively for medical professionals in the United States. With over 70% of U.S. physicians as members across various specialties and practice areas, Doximity offers a suite of tools tailored to enhance productivity and collaboration among healthcare providers. These tools enable doctors to communicate with colleagues, coordinate patient care securely, conduct virtual patient visits, stay informed about the latest medical news and research, and manage their careers effectively. The platform's mission is to support doctors in providing better healthcare by streamlining their professional activities.

Domo, Inc. is a technology company based in American Fork, Utah, that operates a cloud-based platform designed to connect various data, systems, and personnel within organizations. Founded in 2010, Domo's platform enables users, from executives to frontline employees, to access real-time data and insights, facilitating business management through mobile devices. The company offers a subscription-based service that includes a Programmatic Revenue Solution, which integrates complex data from advertising servers and sell-side platforms into user-friendly dashboards. Domo generates revenue primarily through subscriptions to its platform and professional services, allowing organizations to enhance decision-making and operational efficiency.

Dropbox, established in 2007, is a leading provider of secure file sharing, collaboration, and storage solutions. It pioneered cloud storage and cross-platform file syncing, initially targeting individuals and small to medium-sized businesses (SMBs). Over time, Dropbox has expanded its product mix, diversifying beyond its core cloud-storage offerings to cater to a broader range of users and use cases. Its mission is to "unleash the world’s creative energy by designing a more enlightened way of working."

TrialPay, Inc. specializes in cross-platform monetization and stabilization solutions, allowing merchants to connect with consumers through targeted promotions. Founded in 2006 and based in Mountain View, California, with an additional office in Berlin, the company offers a payment platform that enables customers to pay for one item by trying or purchasing something from another merchant. This innovative approach is utilized by various businesses, including those in software, games, online services, publishing, retail, and social networking. TrialPay's monetization toolkit, Evergreen, equips developers with the necessary tools to engage customers effectively, driving acquisition, revenue growth, and long-term value. As of March 2015, TrialPay operates as a subsidiary of Visa Inc.

Peixe Urbano is an online platform based in Florianópolis, Brazil, that allows users to discover and book deals across various sectors, including restaurants, beauty services, entertainment, and travel. Established in 2010, the platform connects consumers with local businesses, enhancing visibility and generating demand for their offerings. Peixe Urbano has gained recognition in the tech industry, having been awarded "Best International Startup of the Year" at the Crunchies Awards. By catering to individual preferences and localities, Peixe Urbano facilitates a seamless experience for users seeking discounts and promotions in multiple consumer service categories.

Zynga Inc., established in 2007, is a leading global developer, publisher, and operator of social games. The company's portfolio spans over 6 billion downloads across 175 countries, featuring popular franchises like FarmVille, Words With Friends, and Zynga Poker. Zynga's games are played on mobile platforms (iOS, Android) and social networking sites, with revenue generated through game downloads, in-game purchases, and advertising services. The company's headquarters are in San Francisco, California, with additional locations in North America, Europe, and Asia.

Portola Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in South San Francisco, California, founded in 2003. It specializes in developing and commercializing innovative therapeutics primarily aimed at treating thrombosis, hematologic disorders, and inflammation. The company's lead product is Andexxa, an antidote for the anticoagulants rivaroxaban and apixaban. Additionally, Portola offers Bevyxxa, a once-daily oral Factor Xa inhibitor designed to prevent venous thromboembolism in adults with acute medical conditions. The firm is also developing several investigational products, including cerdulatinib, an oral dual inhibitor for hematologic cancers, and other compounds targeting chronic inflammatory diseases and cardiovascular conditions. Portola engages in collaborative agreements with various pharmaceutical companies to enhance its research and development efforts. As of July 2020, it operates as a subsidiary of Alexion Pharmaceuticals, Inc.

Portola Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in South San Francisco, California, founded in 2003. It specializes in developing and commercializing innovative therapeutics primarily aimed at treating thrombosis, hematologic disorders, and inflammation. The company's lead product is Andexxa, an antidote for the anticoagulants rivaroxaban and apixaban. Additionally, Portola offers Bevyxxa, a once-daily oral Factor Xa inhibitor designed to prevent venous thromboembolism in adults with acute medical conditions. The firm is also developing several investigational products, including cerdulatinib, an oral dual inhibitor for hematologic cancers, and other compounds targeting chronic inflammatory diseases and cardiovascular conditions. Portola engages in collaborative agreements with various pharmaceutical companies to enhance its research and development efforts. As of July 2020, it operates as a subsidiary of Alexion Pharmaceuticals, Inc.

Terabeam is an American company that designs and manufactures free-space optical transceivers for internet access in downtown areas. Terabeam was founded in 1997 and is located in Kirkland, Washington. As of August 29, 2008, the company operates as subsidiary of Renaissance Electronics & Communications LLC.